Skip to main content

Table 3 Comparative studies involving chemoimmunotherapy and combinations of novel agents

From: Combining BTK inhibitors with BCL2 inhibitors for treating chronic lymphocytic leukemia and mantle cell lymphoma

Comparisons Trial Phase Patients
FCR vs I + V NCT04010968 2 TN CLL(fit)
FCR/BR vs V + R vs V + O vs I + V + O NCT02950051 3 TN CLL(fit)
FCR/BR vs A + V ± O NCT03836261 3 TN CLL
I + V vs Chl + O NCT03462719 3 TN CLL/SLL
I + O vs I + O + V NCT03737981 3 TN CLL/SLL(older)
NCT03701282 3 TN CLL/SLL(younger)
I vs I + V vs V + O NCT04608318 3 TN CLL
A + V vs V + O NCT05057494 3 TN CLL/SLL
  1. A acalabrutinib, BR bendamustine and rituximab, Chl chlorambucil, CLL/SLL chronic lymphocytic leukemia/small lymphocytic lymphoma, FCR fludarabine, cyclophosphamide and rituximab, I ibrutinib, O obinutuzumab, R rituximab, V venetoclax, TN treatment-naïve